CTIBIOTECH & SANOFI wish to utilize their expertise to
improve prediction of the safety, security and tolerance of mRNA
vaccines in development.
- SAFESKIN3D: aims to make human skin injection sites with 3D
bioprinting for better prediction of vaccine tolerance at early
stages of development
- SAFESKIN 3D: will make it possible to model injection sites
(subcutaneous & intramuscular) to screen hundreds of vaccine
formulations a day without animal testing
- CTIBIOTECH™ invests 1 million
Euros in SAFESKIN 3D with additional 500k Euros grant funding by Sanofi (iDEA-TECH
award), France 2030 award (French
government, Region Auvergne Rhone Alpes) & Grant by Métropole
de Lyon.
- SAFESKIN 3D will create a unique world leading technical
platform for development of more effective, safer and
cost-optimized vaccines with the creation of up to 70 jobs by
2031.
LYON,
France, June 26, 2024 /PRNewswire/
-- CTIBIOTECH™, a pioneering company in the development and
production of biological tests on human tissues, is proud to
announce the launch of its innovative SAFESKIN3D project. This
groundbreaking initiative aims to produce flexible 3D bioprinted
human skin models to predict the reactogenicity of vaccines,
particularly the new generation of messenger RNA (mRNA)
vaccines.
Transforming Vaccine Safety Testing
The SAFESKIN3D
project represents a significant technological breakthrough in the
field of vaccine development. By leveraging CTIBIOTECH's expertise
in 3D bioprinting and human tissue engineering, the project will
create advanced human skin models that mimic subcutaneous and
intramuscular injection sites. These models will enable
pharmaceutical companies to better predict the safety, security,
and tolerance of mRNA vaccines, reducing the reliance on animal
testing and accelerating the development of safer vaccines.
Collaboration with SANOFI
CTIBIOTECH™ has secured a
strategic partnership with SANOFI, a global leader in vaccine
development, to act as a "beta tester" for the new injection site
skin models. SANOFI's expert feedback will be instrumental in
validating and refining the models, ensuring they meet the highest
standards of pharmaceutical industry accuracy and reliability.
Project Objectives and Benefits
The SAFESKIN3D project
aims to:
- Develop sophisticated 3D human skin models that include
epidermis, dermis, hypodermis, and muscle layers.
- Integrate immune cells, sensory neurons, and vascular
components to create a comprehensive model for vaccine safety
testing.
- Reduce the cost and time of vaccine development by providing a
high-throughput, human-based testing platform.
- Minimize the need for animal experimentation, aligning with
global ethical standards and regulatory pressures.
Professor Colin McGuckin,
President & Chief Innovation Officer of CTIBIOTECH™, stated,
"The SAFESKIN3D project is a testament to our commitment to
innovation and excellence in making human tissues. By developing
advanced 3D bioprinted skin models, we not only enhance the safety
and efficacy of new vaccines but also pave the way for more ethical
and sustainable research practices. This project will significantly
reduce the reliance on animal testing and accelerate the
development of next-generation vaccines, ultimately benefiting
public health on a global scale. We are thrilled to collaborate
with SANOFI and leverage their expertise to bring this
transformative technology to market."
Economic and Societal Impact
The successful
implementation of SAFESKIN3D will position CTIBIOTECH™, the
Metropole of Lyon and the Auvergne
Rhône Alpes region as world leading territory for innovative
vaccine safety testing. The project is expected to create 5
direct jobs during its execution and up to 70 jobs and
15 million euros revenue by 2031,
contributing to the region's economic growth and technological
advancement. Additionally, the project supports France and Europe's economic sovereignty by enhancing the
local capabilities in vaccine development.
CTIBIOTECH™ invests 1 million
Euros in the SAFESKIN3D project and received 500k euros additional support and financing
from:
- Sanofi iDEA-TECH Award: a competitive call for projects
aimed at transforming technological innovations developed by
academic laboratories, start-ups and biotech companies into
solutions that will accelerate the discovery of new therapies.
- Transforming SMEs through innovation | France 2030 award: to help with the design
of innovations, at the feasibility study or development stage
financed by French Government and Region Auvergne Rhone
Alpes.
- Important Project of Common European Interest ('IPCEI'
Med4Cure award) accelerating medical advancement and at
fostering the resilience of the European Union health
industry with a grant by the Metropole de Lyon
Environmental and Next-Generation Health
Responsibility
SAFESKIN3D aligns with CTIBIOTECH's
commitment to sustainability by repurposing human biological
samples that would otherwise be discarded. This approach not only
reduces waste but also provides a pragmatic alternative to animal
testing, furthering the company's mission to develop ethical and
effective biomedical solutions. Furthermore, clinical development
of SAFESKIN3D could lead to human treatments of the future.
Dr. Nicolas Forraz, Chief Executive Officer of CTIBIOTECH™,
commented, "The launch of the SAFESKIN3D project marks a pivotal
moment for CTIBIOTECH™ and the broader field of vaccine
development. Our innovative 3D bioprinted skin models will provide
a more accurate and ethical method for assessing vaccine safety,
ultimately leading to faster and more cost-effective development of
new vaccines. This project underscores our commitment to scientific
excellence and our dedication to transforming public health. We are
excited to partner with SANOFI and leverage their expertise to
bring this transformative technology to the forefront of vaccine
research. We are grateful to SANOFI, The Metropole of Lyon, The Region Auvergne Rhone Alpes, The
French Government France 2030 initiative and Lyonbiopole Auvergne
Rhone Alpes for their support"
About CTIBIOTECH™
Founded in 2009, from a dream
to be different, CTIBIOTECH™ specializes in the development and
production of human tissues, particularly from human samples
normally thrown away – giving them new life! We make human-based
bioassays for biomedical, pharmaceutical, and dermatocosmetic
research in the short term, while we help to develop the
transplants of the future. With a state-of-the-art facility in
Meyzieu, Lyon, France, and a team
of world-class scientists, CTIBIOTECH™ is dedicated to advancing
personalized and precision medicine through innovative
technologies, including 3D bioprinting.
Contact Information
For more information, please
contact:
Dr. Nico FORRAZ
Chief Executive Officer
CTIBIOTECH™
Email: 379682@email4pr.com
Phone Number: +33 6 78 90 38 50
www.ctibiotech.com
Note to Editors: High-resolution images and interviews with
CTIBIOTECH™ executives are available upon request.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ctibiotech-receives-prestigious-sanofi-idea-tech-award-and-france-2030-awards-to-launch-groundbreaking-1-million-euros-safeskin3d-bioprinting-project-to-revolutionize-vaccine-safety-testing-302182713.html
SOURCE CTIBIOTECH